摘要
Abstract
Objective To observe the effects of ilozumab on blood lipid,inflammation and vascular en-dothelial function in patients with coronary heart disease.Methods A prospective study was conducted on 110 patients with coronary heart disease who visited the hospital from January 2022 to January 2024.Using a com-puter-generated random number table,110 patients were divided into a conventional group(55 cases)and a combination group(55 cases)according to the order of entry into the study.The conventional group received percutaneous coronary intervention(PCI)treatment and conventional antiplatelet therapy.The combination group was treated with ilozumab combined with PCI.The blood lipid levels,inflammatory indicators,endothe-lial function,and treatment safety of patients were compared between the two groups.Results The levels of total cholesterol(TC),triglycerides(TG),and low-density lipoprotein cholesterol(LDL-C)in the combination group were lower than those in the combination group,while the level of high-density lipoprotein cholesterol(HDL-C)was higher than that in the conventional group,the differences were all statistically significant(P<0.05).The levels of interleukin-6(IL-6),C-reactive protein(CRP),tumor necrosis factor-α(TNF-α),and prop-rotein convertase subtilisin/kexin 9(PCSK9)in the combination group were lower than those in the conven-tional group,the differences were all statistically significant(P<0.05).The levels of angiotensin Ⅱ(Ang Ⅱ),endothelin-1(ET-1),plasminogen activator inhibitor-1(PAI-1),and tissue type plasminogen activator(t-PA)in the combination group were lower than those in the conventional group,the differences were all statistically significant(P<0.05).The incidence of drug-related adverse reactions in the combination group[12.73%(7/55)]was not statistically different from that in the conventional group[9.09%(5/55)](P>0.05).Conclusion Ilozumab assisted PCI can effectively reduce blood lipid levels in patients with coronary heart disease with-out increasing medication risk,and has a positive effect on reducing inflammation and endothelial damage in patients.关键词
冠心病/经皮冠状动脉介入/依洛尤单抗/降脂效果/治疗安全性Key words
Coronary heart disease/Percutaneous coronary intervention/Ilozumab/Lipid-lower-ing effect/Treatment safety分类
医药卫生
